期刊文献+

肿瘤标志物免疫测定的标准化 被引量:5

The standardization of tumor markers immunoassay
原文传递
导出
摘要 参考国内外的标准和文献,总结了临床肿瘤标志物免疫测定过程中肿瘤标志物免疫测定标准化的各个因素。临床标本采集、运送和保存的标准化、检测试剂和方法的标准化、检测结果分析的标准化以及标准物质是肿瘤标志物免疫测定标准化的4个要素。在肿瘤标志物免疫测定标准化各要素中,标准物质是获得具有可比性结果的前提,试剂方法、结果分析和工作程序的标准化,也是不可或缺的要素。标准化是实现肿瘤标志物免疫测定结果可比性的前提,而标准化并非是单一因素,其由诸多关键性环节组成,核心是标准物质的研制及应用。通过阐明肿瘤标志物免疫测定标准化的各个因素,为提高肿瘤标志物免疫测定的准确性和结果的可比性提出了建议。 Referring to the standard and documentation,the various factors in the process of tumor markers immunoassays standardization were aggregated.The standardization of clinical sample collection,transportation and preservation,test reagents and methodology,reference materials application were four elements in tumor markers immunoassay standardization.As to the four elements,reference materials was premise to obtain comparable results.And it was essential that results analysis,reagent and methods,and standardization of procedures.Standardization is the premise to realize comparability of tumor markers immunoassay results.Standardization was composited by many critical factors,the core was reference materials development and application.By clarifing the tumor markers immunoassay standardization of various factors,suggestion to improve tumor markers immunoassay accuracy and comparability of the results was proposed.
出处 《药物分析杂志》 CAS CSCD 北大核心 2010年第9期1800-1803,共4页 Chinese Journal of Pharmaceutical Analysis
基金 体外诊断试剂国家标准品 参考品标定及复核项目(2011604)资助
关键词 肿瘤标志物 标准化 标准物质 tumor markers immunoassay standardization reference materials
  • 相关文献

参考文献14

  • 1Pritzker KP. Cancer biomarkers: easier said than done. Clin Chem, 2002,48 (8) : 1147.
  • 2范振符,陈智周.肿瘤标志物的研究与临床应用评价[J].标记免疫分析与临床,2002,9(2):108-111. 被引量:27
  • 3吴健民.影响肿瘤标志物检测的因素[J].中华检验医学杂志,2005,28(4):352-354. 被引量:23
  • 4LI Jin-ming(李金明).Clinical Enzyme Immunoassay Technique(临床酶免疫测定技术).Beijing(北京):People’s Military Medical Press(人民军医出版社),2005.87.
  • 5高尚先,黄杰.体外诊断试剂标准物质国内外现状[J].药物分析杂志,2008,28(7):1207-1213. 被引量:10
  • 6Council Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on In Vitro Diagnostic Medical Devices. Official Journal of the European Union L33,1998.5.
  • 7徐蓓,陈文祥.临床检验溯源系统的建立[J].中国计量,2007(4):34-35. 被引量:4
  • 8QUAN Hao(全浩),HAN Yong-zhi(韩永志).Reference Materials and Application(标准物质及其应用技术).2nd Ed(第二版).Beijing(北京):Standards Press of China(中国标准出版社),2003.89.
  • 9WHO. Recommendations for the Preparation, Characterization and Establishment of International and Other Biological Reference Standards( Revised 2004 ). 2004.36.
  • 10Lein M,Jung K, Elgeti U, et al. Ratio of alpha 1 - antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis. Anticancer Res, 2000,20 ( 6 D ) :4997.

二级参考文献24

  • 1王抒,李培瑛,陈文祥,董军,蒋雷,国汉邦,唐蔚青,李红霞,李健斋.血清胆固醇标准参考物质的研制[J].中华医学检验杂志,1996,19(4):216-219. 被引量:7
  • 2范振符 巴德年.肿瘤的免疫学检测.当代免疫学技术与应用[M].北京:北京医科大学中国协和医科大学联合出版社,1998.927-948.
  • 3Selby C. Interference in immunoassay. Ann clin Biochem,1999.36:704-721.
  • 4李金明.肿瘤标志物免疫测定的质量控制及标准化[A]..肿瘤标志专题讨论会论文集[C].,2002.41-53.
  • 5Sturgeon CM, Seth J. Why do immunoassays for tumor markers give differing results?--a view from the UK National External Quality Assessment Schemes. Eur J Clin Chem Biochem, 1996, 34:755-759.
  • 6Sturgeon CM. Tumor markers in the laboratory: closing the guideline-practice gap. Clin Biochem, 2001,34:353-359.
  • 7Wood WG. "Matrix effects" in immunoassay. Scan J Clin Lab Invest Suppl, 1991,205:105-112.
  • 8Bidart JM, Thuillier F, Augereau C, et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin chem,1999,45:1695-1707.
  • 9European Union. Directive 98/79/EC of the european parliament and of the council of 27 October 1998 on in vitro diagnostic medical devices. OffJ Euro Commun, 1998,1331 : 1237
  • 10ISO. in vitro diagnostic medical devices measurement of quantities in samples of biological origin - metrological traceability of values assigned to calibrators and control materials. ISO/DIS 17511, Geneva, 2000

共引文献59

同被引文献54

  • 1郭玉华,屈凌波,吴拥军,薛乐勋.化学发光免疫分析在肿瘤标志物检测中的应用[J].国外医学(放射医学核医学分册),2004,28(5):220-221. 被引量:9
  • 2吴健民.对肿瘤标志物的再认识[J].中华检验医学杂志,2005,28(1):11-13. 被引量:117
  • 3吕文平,董家鸿.肝细胞癌分期评价与展望[J].消化外科,2005,4(5):374-378. 被引量:3
  • 4Hara N, Kasailara T, Kawasaki T, et al. Reverse transcription- polymerase chain raetion detection of proslale-specific antigen, prqstate-specific membrane antigen, and proslale slem cell antigen in one milliliter of peripheral blood: value flJr the staging of prostate cancer[ J]. Clin Cancer Res,2002,8(6) :1794-1799.
  • 5Feitelson M A. Hepatitis B x antigen and p53 in the developm:nt of hepatocellular t:arcinoma [ J ]. J Hepatobiliary Pancreat Surg, 1998, 5 ( 4 ) : 367-374.
  • 6Bedard L L, Alessi M, I)avey S,et al. Susceptibility Io af]atoxin BI- induced carcinogenesis correlates witll tissue-specific differences in DNA repair activily in mouse and in rat[ J ]. Cancer Rcs, 2005,65 (4) :1265-1270.
  • 7lizuka N, Oka' M, Yamada-Okabe H, et al. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus- infected hepatoeellular carinmla by oligonueleotidc microarray dda on the basis of a supervised learning method[ J]. Cancer Res, 2002, 62(14) :3939- 3944.
  • 8Honda M, Kaneko S, Kawai H, et al. Differential gene cxpu'cssion between chronic hepatitis B and C hepatic lesion [ J ]. Gastroenterology, 2001 , 120 ( 4 ) : 955 -966.
  • 9Gomaa A 1, Khan S A, l,cen E L, et al Diagnosis of hepatocdlular carcinoma [ J ]. World J Gasmenterol, 2009, 1 5 ( 11 ) : 1301 -1 314.
  • 10Hirashima N, Matsumoto Y, Ohono T, et al. ttepati Fas protein expression might be a predictive ['actor for het,atocellular ,:arcinoma development in patients with hronic hpatilis C un,lergoiug inlerteron therapy [ J ]. J Clin Gastrocntend, 2002,34 ( 3 ) : 263-267.

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部